Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Yuanyuan ZhaoBing ZhaoGang ChenYinlan ChenZijun LiaoHaiming ZhangWeineng FengYinyin LiHeng WengWeidong LiYuefen ZhouBiyong RenYanda LuJianhua ChenZhenteng LiuZhenzhong SuWenliang WangLi ZhangPublished in: Cancer communications (London, England) (2022)
Fosaprepitant-based triple prophylaxis demonstrated non-inferior control for preventing CINV in patients treated with cisplatin-base chemotherapy. Female cancer patients without a history of alcohol consumption, with larger BSA and received high-dose cisplatin might be more vulnerable to CINV. Three personalized prediction models were well-validated and could be used to optimize antiemetic therapy for individual patients.
Keyphrases
- chemotherapy induced
- phase iii
- high dose
- double blind
- alcohol consumption
- clinical trial
- open label
- phase ii
- placebo controlled
- end stage renal disease
- low dose
- stem cell transplantation
- newly diagnosed
- ejection fraction
- chronic kidney disease
- papillary thyroid
- study protocol
- prognostic factors
- randomized controlled trial
- squamous cell
- patient reported outcomes
- young adults